Bile duct disorder

disease
On this page

Also known as bile duct diseasebile duct disease or disorderdisease of bile ductdisease or disorder of bile ductdisorder of bile duct

Summary

Bile duct disorder (MONDO:0002887) is a disease (an umbrella term covering 7 Mondo subtypes) with 5 GWAS associations across 4 studies and 38 clinical trials. Top therapeutic interventions include pinaverium, ursodiol, and ascorbic acid. A subtype of biliary tract disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Umbrella term: 7 Mondo subtypes
  • GWAS associations: 5
  • Clinical trials: 38

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namebile duct disorder
Mondo IDMONDO:0002887
MeSHD001649
DOIDDOID:4138
NCITC96716
SNOMED CT118926004
UMLSC0005395
MedGen2240
Anatomy (UBERON)UBERON:0002394
Is cancer (heuristic)no

Also known as: bile duct disease · bile duct disease or disorder · bile duct disorder · disease of bile duct · disease or disorder of bile duct · disorder of bile duct

Data availability: 5 GWAS associations (4 studies).

Disease family

This is a subtype of biliary tract disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorderhepatobiliary disorderbiliary tract disorderbile duct disorder

Related subtypes (14): biliary tract neoplasm, gallstones, primary biliary cholangitis, bile reflux, postcholecystectomy syndrome, Alagille syndrome, isolated agenesis of gallbladder, cholelithiasis, ketamine-induced biliary dilatation, follicular cholangitis and pancreatitis, idiopathic ductopenia, Caroli syndrome, isolated congenital hepatic fibrosis, Rokitansky-Aschoff sinuses of the gallbladder

Subtypes (7): perforation of bile duct, cholestasis, common bile duct disorder, non-neoplastic bile duct disorder, bile duct cyst, bile duct neoplasm, fibrosis of bile duct

Genetics & variants

GWAS landscape

5 GWAS associations across 4 studies. Top hits map to 3 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs7767665814e-12MAML3C3.85
rs3715108085e-12ADCY9A3.69
rs5780926972e-11PRKAG2C1.93
rs5758967482e-11PKMYT1 - GREP1T3.27
rs5364276634e-11ZSWIM5P3 - LINC02466T3.58

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90478476Verma A20241,206448,768Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90436389Zhou W2018777391,307Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90480353Verma A2024305121,355Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90482186Verma A2024305121,355Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding0
Tier 2: splice/UTR0
Tier 3: regulatory0
Tier 4: intronic/intergenic5

MAF distribution

BucketVariants
common (>=0.05)0
low_freq (0.01-0.05)0
rare (<0.01)5
unknown0

Functional consequences

ConsequenceCount
intron_variant4
intergenic_variant1

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs7767665814139743181C>G,T0intron_variantMAML34e-12Tier 4: intronic/intergenic
rs371510808163978561A>C0intron_variantADCY95e-12Tier 4: intronic/intergenic
rs5780926977151619403C>T0.001intron_variantPRKAG22e-11Tier 4: intronic/intergenic
rs575896748162982040T>C,G0intron_variantPKMYT1 - GREP12e-11Tier 4: intronic/intergenic
rs5364276634129611431T>C0intergenic_variantZSWIM5P3 - LINC024664e-11Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugDevelopment status
DrotaverinePhase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Diclofenac.

Clinical trials & evidence

Clinical trials

Clinical trials: 38.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified33
PHASE33
PHASE22

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00731198PHASE3COMPLETEDDrotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During Endoscopic Retrograde Cholangiopancreatography (ERCP)
NCT00945516PHASE3COMPLETEDNewly Designed Fully Covered Metal Stent for the Benign Biliary Stricture
NCT01745978PHASE3UNKNOWNCompare the Knob-tipped Knife With the Needle Knife in Difficult Biliary Cannulation
NCT00040131PHASE2TERMINATEDSafety and Efficacy Study of IL-10 (Tenovil TM) in the Prevention of Post-ERCP Acute Pancreatitis (Study P02580)(TERMINATED)
NCT03678480PHASE2WITHDRAWNA Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC)
NCT04556019Not specifiedRECRUITINGResults of Surgical Treatment of the Hepatobiliopancreatic Surgical Unit
NCT05014347Not specifiedACTIVE_NOT_RECRUITINGPatient Reported Experience in Endoscopic Ultrasound
NCT05689255Not specifiedRECRUITINGGut Microbiome and Metabolome in Patients With Gallstone Disease After Surgical and Endoscopic Interventions
NCT06010576Not specifiedRECRUITINGEndoscopic Ultrasound-guided Rendezvous Versus Precut Papillotomy
NCT06340620Not specifiedRECRUITINGEUS Examination Using EndoSound Vision System vs. Standard Echoendoscope
NCT07263061Not specifiedRECRUITINGTime to Post-operative Recovery of Serum Albumin as a Predictor of Outcome in Major Hepato Pancreato Biliary Surgeries
NCT07511907Not specifiedNOT_YET_RECRUITINGRoutine Intraoperative White Test for Bile Leak Detection in Liver Resection
NCT00270868Not specifiedUNKNOWNEfficacy of Double Wire Technique in Difficult Cases of Common Bile Duct Cannulation in ERCP (UDOGUIA-04)
NCT00930410Not specifiedCOMPLETEDIntra-ductal Confocal Endomicroscopy for Characterization of Pancreas and Bile Duct Tumor
NCT01438385Not specifiedUNKNOWNInterventional Endoscopy Database for Pancreatico-biliary, Gastrointestinal and Esophageal Disorders
NCT01493076Not specifiedCOMPLETEDSafety and Efficacy of a Newly Developed Baby-sphincterotome for Bile Duct Cannulation
NCT02189421Not specifiedUNKNOWNMultibending vs Conventional Endoscope for Direct Peroral Cholangioscopy
NCT02611453Not specifiedUNKNOWNCholangiography Using Carbon Dioxide Versus Iodinated Contrast in ERCP
NCT02882451Not specifiedUNKNOWNImpact of Pinaverium Bromide on Bile Duct and Pancreatic Duct Cannulation During Endoscopic Retrograde Cholangiopancreatography
NCT02917408Not specifiedCOMPLETEDRetrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital
NCT03775681Not specifiedCOMPLETEDFeasibility of Laryngeal Mask Airway Gastro on Patients Undergoing Endoscopic Retrograde Cholangiopancreatography for Pancreas and Bile Duct Disorders
NCT03951324Not specifiedUNKNOWNVolumetric Laser Endomicroscopy’s (VLE) Diagnostic Accuracy Validation Study: Impact on Clinical Management Study
NCT04040504Not specifiedCOMPLETEDInfection Control in ERCP Using a Duodenoscope With a Disposable Cap
NCT04145843Not specifiedCOMPLETEDTreatment Outcomes in Bile Duct Stones
NCT04341909Not specifiedCOMPLETEDTrainee Involvement in ERCP Risk Score
NCT04580940Not specifiedCOMPLETEDSpyGlass™ Discover Percutaneous
NCT04929821Not specifiedUNKNOWNUNITY-B A Prospective, Multicentric, Single-arm Study to Evaluate the Safety and Efficacy of the UNITY-B Biodegradable Balloon-Expandable Biliary Stent System in Subjects With Biliary Strictures
NCT05051358Not specifiedUNKNOWNTherapeutic Endoscopic Ultrasound for Gastrointestinal Disorders: A Multicenter Registry Study
NCT05263752Not specifiedCOMPLETEDEvaluation of Safety and Efficacy of NvisionVLE® Imaging Low Profile System in Patients With Bile Duct Disease
NCT05457101Not specifiedUNKNOWNValidation of an AI-based Biliopancreatic EUS Navigation System for Real-time Quality Improvement: A Prospective, Single-center, Randomized Controlled Trial
NCT05475964Not specifiedUNKNOWNThe Role of Endoscopic Ultrasound in Evaluation of Patients With Indefinite Cause of Bile Duct Dilatation
NCT05600270Not specifiedCOMPLETEDAngled-tip vs. Straight-tip Guidewire in Biliary Cannulation
NCT05822635Not specifiedCOMPLETEDSpyGlass Surgical Study
NCT06106750Not specifiedUNKNOWNEndoscopic Scissors Cutting Nasobiliary Duct VS Bilateral Plastic Stent
NCT06115655Not specifiedUNKNOWNA Single-center, Prospective Cohort Study on the Differentiation of Benign and Malignant Bile Duct Stenosis Based on Bile and Peripheral Blood cfDNA Methylation Profiles
NCT06170632Not specifiedUNKNOWNFlare Type Self-expandable Metal Stents (SEMS) vs Plastic Stent for the Treatment of Difficult Common Bile Duct Stone
NCT06364865Not specifiedCOMPLETEDAE05ML Device for ML Hem-o-lok Polymer Clip Delivery in Laparoscopic Surgical Procedures Observational Registery Study
NCT07417020Not specifiedCOMPLETEDRole of Prophylactic Aggressive Hydration to Prevent Post-ERCP Pancreatitis

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
PINAVERIUM43
URSODIOL42
ASCORBIC ACID41
BERBERINE URSODEOXYCHOLATE21
INTERLEUKIN-1021
CHEMBL548304001
CHEMBL540958301
CHEMBL430338301